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1. Introduction
   Macrosomia defined as weight of a full-term infant 
greater than 90th percentile for gestational age or higher 
than 4 000 g occurs in 6%-10% of all deliveries[1,2]. Foetal 
macrosomia is associated with a higher frequency of 
operative deliveries, post partum haemorrhages, birth injury 
during vaginal delivery, and neonatal hypoglycaemia. 
Known maternal risk factors are only identified in 40% of 
women who deliver macrosomic babies. For instance, in 
North America, African Americans have been reported 
to have higher risk of delivering macrosomic babies[3]. In 
PEER REVIEW                            ABSTRACT
KEYWORDS
Non-gestational diabetes, Macrosomia, Glucose tolerance test characteristics, Pregnancy 
Objective: To look into the glucose tolerance test characteristics and determine complications in 
non-gestational diabetes pregnant subjects.
Methods: From 2006 to 2009 all non-gestational diabetes mellitus (non-GDM) pregnant women 
who delivered macrosomia at the North Australia’s Townsville Hospital were retrospectively 
reviewed by extracting data from clinical record. Glucose tolerance tests results were analysed in 
the light of an earlier diagnosis of non-GDM.
Results: Ninety-one non-GDM mothers with macrosomia were studied and compared with 41 
normoglycemic subjects without macrosomia. Of the subjects with non-GDM macrosomia, 45 (49.4%) 
had normal 50 g glucose challenge test (GCT) without further testing, another 8 (8.8%) had abnormal 
GCT but normal 75 g oral glucose tolerance test (OGTT). A total of 4 (4.4%) subjects had normal GCT 
and OGTT. Interestingly, 14 out of 16 (87.5%) subjects who were tested with OGTT owing to past 
history of macrosomia had normal results but delivered macrosomic babies. Only 12 subjects 
had both GCT and OGTT, the rest of the cohort had either of the two tests. Subjects with non-GDM 
macrosomia had higher frequency of neonatal hypoglycaemia 34% as compared to 10% in non-
macrosomic babies (P=0.003). Other feto-maternal complications were similar in both groups.
Conclusions: No significant pattern of glucose tolerance characteristics was identified in non-
GDM mothers with macrosomic babies. In spite of being normoglycemic significant neonatal 
hypoglycaemia was recorded in non-GDM macrosomic babies. Further prospective studies on a 
larger population are needed to verify our findings.
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of blood glucose tests in non-GDM 
macrosomic subjects in the Asia 
Pacific region. Such study is relevant 
in the region noted to have the highest 
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the world.
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Australasia where obesity and metabolic syndrome has been 
a growing concern, recent studies have shown higher rate of 
macrosomia in the population sub-group[4]. 
   Diagnosing gestational diabetes mellitus (GDM) may involve 
an initial screening of all pregnant women between 24 to 28 
weeks gestation with a 50 g oral glucose challenge test (GCT). 
A venous glucose >7.7 mmol/L at 1 h is then followed up by 
a 75 g oral glucose tolerance test (OGTT). A fasting glucose 
level of >5.5 mmol/L, or a 2 h level >8.0 mmol/L confirmed 
GDM in Australia and >9.0 mmol/L, in New Zealand[5]. 
However, recently the validity of using diagnostic criteria 
to diagnose GDM is questioned due to amongst other factors 
poor predictive value of macrosomia in subjects with non-
GDM[6,7]. Nevertheless various tests have been used with 
different threshold aiming at predicting macrosomia which is 
noted for having high feto-maternal complications. Although 
glucose tolerance studies have been conducted to diagnose 
GDM, few studies have investigated its pattern in subjects 
with normoglycemia in pregnant women with macrosomia. In 
view of the need to identify macrosomia in order to prevent 
peri-natal complications, usefulness of blood glucose profile 
in non-diabetic pregnant women might be helpful. The aim 
of the study was to determine blood glucose tolerance test 
characteristics and associated perinatal complications in 
women with non-GDM macrosomic babies at delivery.
2. Materials and methods
   A retrospective observational analysis was performed on 91 
clinical case notes of non-GDM subjects, who had given birth 
to macrosomic infants defined as birth weights exceeding 
90th percentile for a given gestational week. A total of 41 
subjects with normal birth weights served as controls. The 
patients were randomly selected on the first 91 available 
case notes received, between 2006 and 2009. 
   Subjects were assessed for maternal age, height, body 
mass index (BMI), parity, previous history of macrosomic 
birth, lifestyle and mode of delivery. Complications at birth 
assessed for included post partum haemorrhage, neonatal 
birth injuries, neonatal hypoglycaemia and neonatal 
respiratory distress. Post partum haemorrhage was defined 
as the loss of 500 mL or more of blood after vaginal delivery, 
and the loss of more than 1 000 mL of blood after a caesarean 
section delivery[8].
   BMI was calculated from the booking in or pre-pregnancy 
weight, as recorded on the maternal hand held charts. 
Paternal BMI was unavailable. There was insufficient 
documentation of weight gain with respect to non-GDM large 
for gestational age subjects and thus it was not included in 
the analysis.  
   We assessed the total number of our study subjects who 
had given birth to macrosomic infants despite normal 50 
g GCT and/or a normal 75 g OGTT. An abnormal GCT was 
defined as a 1 h venous glucose value equal to or greater 
than >7.7 mmol/L. An abnormal OGTT was defined as a 
fasting glucose of ≥5.5, or a 2 h value ≥8.0 mmol/L. Subjects 
diagnosed to have GDM were excluded from the study. Data 
were represented as absolute numbers and percentages 
while Chi-square test was performed to test for association 
between two categorical factors. For continuous data that 
were not normally distributed, Mann-Whitney test was 
performed using SPSS version 12.0 (Chicago, IL, USA). Results 
were considered statistically significant at a P value less 
than 0.05. 
3. Results
   One hundred and thirty two subjects were reviewed 
comprising 91 with non-GDM macrosomic babies while 
41 delivered non-macrosomic babies (Table 1). An 
overwhelming majority of our study population was 
Caucasian 85.6% (113/132) compared to 9.8% (13/132) of 
Indigenous Australians with relative risk. About 13.1% (12/91) 
of our study participants with non-GDM macrosomia were 
of ATSI ethnicity compared to 84.6% (77/91) of the Caucasian 
subjects. Others 5.5% (5/91) comprising two each of Maori of 
New Zealand and Pacific Islander descent, and one Asian. 
There were no significant differences in the Caucasian 
population at risk of macrosomia. About 20.9% (19/91) of 
subjects with non-GDM macrosomia gave a history of being 
smokers during the course of the pregnancy, 16.5% (15/91) 
consumed unspecified amounts of alcohol, and 4.4% (4/91) 
gave a history of recreational drug usage.  
Table 1
Characteristics and foeto-maternal complications of non-GDM macrosomia 
subjects compared with non-macrosomic controls.
Parameters Macrosomia (n=91) Non-macrosomia  (n=41) P value
Maternal age >35 years 10 (11%)   9 (22%)     0.1
Indigenous: Caucasian 12:77 1:37  0.06
Parity >1 38 (42%) 18 (44%)     0.8
BMI >25 kg/m2 66 (73%) 31 (76%)     0.7
Fetal gender: male/female 54/51 24/21     0.8
Previous macrosomia 31 (34%) 11 (27%)     0.4
Post-partum hemorrhage 23 (25%)   7 (17%)     0.3
Neonatal hypoglycaemia at birth 31 (34%)   4 (10%)    0.003
Birth injury 10 (11%)    1 (2%)  0.10
Respiratory distress at birth 41 (45%) 12 (29%)  0.09
Caesarean delivery 32 (35%) 16 (39%)  0.67
   Age distribution and anthropometric data were similar 
in both groups. Majority of the subjects in both groups 
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were aged less than 35 years. Two-third of the mothers 
with non-GDM macrosomic babies and normal controls 
had initial antenatal clinic booking in or pre-pregnancy 
BMI greater than 25. Almost all the subjects with non-GDM 
macrosomic babies 97.7% (88/91) of subjects gave birth at 
37-42 weeks gestation. About one-third [35% (32/91)] of 
subjects underwent Caesarean section delivery while the 
remaining had normal vaginal delivery with or without 
an assisted birth. One-quarter of the subjects with non-
GDM large for gestational age subjects and thus it was 
not included in the analysis (23/91) suffered from post-
partum haemorrhage. Other complications included 34% 
(31/91) of our subjects’ neonates suffered from neonatal 
hypoglycaemia, defined as the first measured venous 
blood glucose of the infant less than 3 mmol/L compared 
to 10% in non-macrosomic neonates (P<0.01). All of the 
31 neonates necessitated neonatal intensive care unit 
admission, with uneventful outcome. Birth injuries in the 
non-GDM macrosomic neonates occurred in 11.0% (10/91) of 
births, predominantly from shoulder dystocia. Respiratory 
distresses, defined as the slightest need of oxygen to 
assist breathing in the neonate, and including need for 
intubation, were present in 45% (41/91) and 29% (12/41) of 
cases in subjects with non-GDM mothers with macrosomia 
and non-macrosomic controls respectively (P>0.05). Only 
23% (21/91) of neonate subjects had antenatal ultrasound 
features of macrosomia while the remaining 68 had non-
macrosomic findings. 
   Details of the glucose profile of the subjects with 
macrosomic babies revealed 50 g GCT as a screening test 
was performed in the first instance on 73% of cases (66/91 
subjects), with 17% (11/66) recording 1 h post challenge 
glucose value of ≥7.7 mmol/L. Another 16 out of 91 subjects 
considered at risk for GDM, preceded directly to the 75 g 
OGTT, without undergoing the 50 g GCT. The remaining nine 
subjects were transferred from interstate, and did not have 
available GCT or OGTT information. 
   We identified four patterns of glucose test profiles in our 
non-GDM women with macrosomic babies: 
   (a) 45 subjects who had a normal 50 g GCT (<7.8 mmol/L) 
went on to deliver macrosomic infants. 
   (b) Eight subjects with an abnormal 50 g GCT (>7.7 mmol/
L), but a normal 75 g OGTT, delivered macrosomic babies.
   (c) 14 out of the 16 subjects, who had their 75 g OGTT 
tests done in the first instance, owing to risk factors for a 
macrosomic infant, delivered macrosomic infants, despite 
having had normal biochemical 75 g OGTT response. 
   (d) Four subjects who underwent a 75 g OGTT despite 
a normal biochemical 50 g GCT response, delivered 
macrosomic infants, despite the normal 75 g OGTT result. 
4. Discussion
   
   We have reported poor predictive value of macrosomia 
in non-GDM mothers using glucose tests. Subjects with 
macrosomic babies had virtually normal screening and 
diagnostic values of glucose tolerance. Our report further 
highlighted the need to look for other risk factors beyond 
blood glucose profile. Although not the commonest, 
GDM is the strongest risk factor for macrosomia with 
a twofold increase in the incidence[6,9]. Many of the 
other risk factors (e.g., prolonged gestation, obesity and 
multiparity) are highly prevalent among parturient, thus 
limiting their utility as shown in our study population. 
   Interestingly, our study detected four distinct patterns 
of glucose test characteristics in non-GDM macrosomia 
using 50 g GCT and 75 g OGTT. Firstly, almost 50% of cases 
had a normal 50 g GCT, and did not undergo further tests. 
Secondly, eight other subjects had an abnormal response 
to GCT, but a normal response to OGTT. Thirdly, another 
16 subjects, deemed to have risk factors for macrosomia, 
had a normal biochemical response to the 75 g OGTT 
in the first instance yet delivered macrosomic babies. 
Fourthly, four subjects had normal results for both tests 
but had macrosomic babies at delivery. Analysis from 
Huynh et al. indicates that the 75 g OGTT may be the 
best procedure, without prior GCT although about 10% 
of our cohort had abnormal GCT indicating sub-clinical 
dysglycemia[10]. Systematic review on prediction of 
macrosomic outcomes between using the International 
Association Of Diabetes And Pregnancy Study Groups 
criteria and World Health Organisation guidelines for 
diagnosis of GDM were shown not sensitive enough in 
predicting macrosomia in subjects at risk[11,12].
   Previous history of macrosomia was the strongest 
predictor for non-GDM macrosomia in our cohort with 
normal OGTT/GCT. Indeed 87.5% of our subjects with past 
history of delivering macrosomic babies had normal 
OGTT. Our result is in support of Ogonowski et al. and 
others reports in Caucasians, African Americans, Chinese 
and Asians where past history of macrosomia showed 
higher diagnostic value[1,9,13]. Koyanagi et al. recently 
reported increasing prevalence of non-GDM macrosomia 
worldwide suggesting that maternal hyperglycemia is 
not the only causative factor for macrosomic infants[14]. 
Apart from genetic predisposition, other independent 
predictors of macrosomia have been identified such as 
pre-pregnancy overweight or obesity, excessive weight 
gain during pregnancy, prior GDM, advanced age, family 
medical history of diabetes and prior pregnancy[14,15].
   As previously reported, our study showed significant 
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foeto-maternal complications in subjects with non-GDM 
macrosomic babies. We recorded significant neonatal 
hypoglycemia at delivery in spite of documented normal 
maternal glycemic profile in keeping with possible 
pathogenetic role of glucose-insulin interaction in 
non-GDM macrosomia[16,17]. In contrast, Kew et al. 
demonstrated that non-GDM mothers who gave birth 
to macrosomic infants do not display the post partum 
metabolic dysfunction of women with established GDM, 
indicating dysglycemia, insulin resistance and beta 
cell dysfunction are not restricted to only GDM[18]. Our 
result however further supports having glucose profile 
as part of work up for pregnant women with macrosomia 
and to further follow up postnatally for diabetes[17]. 
Thus, a macrosomic delivery, in the absence of GDM, is 
not necessarily indicative of benign metabolic profile. 
Data from Wollschlaeger et al. that included 956 cases 
of macrosomia[19], detected increased umbilical vein 
insulin levels in a third consistent with previous studies 
showing elevated cord insulin and C-peptide levels[16,17], 
indicative of foetal hyperinsulinemia, and hence, 
support the possibility of undetected maternal glucose 
intolerance during the pregnancy. 
   The limitations of the study were that the glucose test 
profile was not repeated during the period of pregnancy 
and two subjects did not have glucose profile at entry 
though no report of elevated serum glucose was found 
in the chart and at delivery. Also the discrepancy in BMI 
- as weight derived from the first antenatal visit may 
not necessarily be the pre-pregnant body weight. The 
study was retrospective, therefore important variables, 
such as glycosylated haemoglobin and fixed durations 
of gestation for weight measurements in pregnancy were 
not always indicated. Lastly, it is important to note that 
there is a limitation to retrospective studies in general. 
Observations derived from such studies may contain 
some missing information and thus may serve as a 
stimulus to further prospective work to clarify findings. 
The present work must be interpreted in the knowledge 
of the defects inherent in such studies. Despite these our 
result is consistent with other reports[13,20]. 
   In conclusion, we report history of previous macrosomia 
yielding higher pre-test probability of macrosomia in 
subjects with normal glucose tolerance tests during 
pregnancy. Macrocosmic adverse events observed in our 
series were similar to previously reported in literature. 
There is need to devise better ways of defining non-
GDM macrosomia beyond GCT/OGTT. Further prospective 
studies on a larger population to characterise glucose 
homeostasis in non-GDM macrosomic mothers are needed 
to confirm our findings.
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Comments 
Background
   Non-GDM is a growing concern in Asia Pacific region 
where diabetes prevalence is the highest in the world. 
Non-GDM macrosomia is a diagnosis of exclusion based 
on blood glucose profile in early part of pregnancy. 
In those diagnosed as having large for gestational 
age babies not due to GDM, there is need to further 
characterise glucose tolerance profile which may assist 
in predicting macrosomia with its associated peri-natal 
complications.
  
Research frontiers
   Maternal hyperglycemia has been implicated as the 
major cause of neonatal macrosomia, yet clinicians 
frequently report large for gestational age infants in 
normoglycemic pregnancies. Review of glycemic profile 
in such population may assist in predicting macrosomia 
and outcomes in non-GDM. This study will lead to 
revision of the International Association Of Diabetes 
And Pregnancy Study Groups criteria and World Health 
Organisation guidelines for diagnosis of GDM as they were 
shown not sensitive enough in predicting macrosomia 
in subjects at risk insulin resistance particularly in the 
Asia Pacific region.
Related reports
   The authors reported significant neonatal complications 
in subjects with non-GDM macrosomic babies confirming 
possible links in the pathogenesis of macrosomia in both 
diabetic and diabetic pregnancies.
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Innovations and breakthroughs
   This study is novel in the region and only very few 
studies of this nature worldwide conducted detailing 
blood glucose characteristics in non-GDM mothers with 
macrosomic babies.
  
Applications
   The finding in this study is applicable in the high 
risk population of Asia Pacific region where the need to 
diagnose macrosomia is vital so as to prevent maternal 
and fetal complications.    
Peer review
   This is a valuable research in which authors have 
demonstrated the pattern of blood glucose tests in non-
GDM macrosomic subjects in the Asia Pacific region. Such 
study is relevant in the region noted to have the highest 
prevalence of gestational diabetes in the world.
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